Identification of a luminescent platinum(II) complex with BODIPY derivative as novel photodynamic therapy agent for triple negative breast cancer cells
Identification of a luminescent platinum(II) complex with BODIPY derivative as novel photodynamic therapy agent for triple negative breast cancer cells
复制标题
鉴定发光铂（II）与 BODIPY 衍生物的配合物作为三阴性乳腺癌细胞的新型光动力治疗剂
DOI：
10.1016/j.jinorgbio.2023.112160
复制
发表时间：
--
影响因子：
3.9
通讯作者：
Xiaobo Wang
中科院分区：
文献类型：
--
作者：
Yujing Wang;Shuping Wang;Qingqing Wang;Wanyu Tang;Li Lin;Xiaobo Wang
三阴性乳腺癌(TNBC)预后差，肿瘤复发率高，是恶性程度最高的乳腺肿瘤之一。迫切需要开发新的策略或有效的药物来克服耐药性，提高治疗效果。基于硼-二吡咯亚甲基(BODIPY)的光敏剂具有令人兴奋的光物理特性，适合用于治疗，即光动力疗法(PDT)。我们设计了一个发光的单功能铂(II)与BODIPY衍生物，命名为I2BC-铂，作为新型的高PDT试剂，以对抗三阴性乳腺癌(TNBC)。在绿光下(520 Nm)，I2BC-Pt对肿瘤细胞表现出良好的光动力学效应，其IC50值分别为0.11~0.13μM。I2BC-Pt主要聚集在线粒体中，并发出绿色荧光。此外，抗癌机制研究表明，I2BC-Pt可通过抑制RAD51、FOXM1和BRCA1/2，促进DNA修复，并诱导P53介导的TNBC细胞凋亡。综上所述，I2BC-Pt有望作为一种基于BODIPY的光敏剂用于TNBC治疗。
Triple-negative breast cancer (TNBC) is one of the most malignant breast tumors for its poor prognosis and high tumor recurrence. It is urgent to develop new strategy or effective agents to overcome resistance and improve therapeutic effectiveness. Boron-dipyrromethene (BODIPY) based photosensitizers possess exciting photophysical features suitable for theranostic applications, namely, photodynamic therapy (PDT). We have designed a luminescent monofunctional platinum(II) complex with BODIPY derivative, namelyI2BC-Pt, as novel high PDT agent against triple negative breast cancer (TNBC). The di-iodinated BODIPY complexI2BC-Ptshowed excellent PDT effect against TNBC cells in green light (520 nm) giving IC50values of 0.11–0.13 μM in MDA-MB-231 and MDA-MB-468 cells.I2BC-Ptpredominately aggregated in the mitochondria of MDA-MB-231 cells and emitted green fluorescence. Besides, the anticancer mechanism studies demonstrated thatI2BC-Ptcould help DNA repair through attenuating RAD51, FoxM1 and BRCA1/2, and induce p53-mediated apoptosis of TNBC cells. Taken together,I2BC-Ptcould be potentially developed as a BODIPY-based photosensitizers for TNBC therapy.